Related Experiment Video
Updated: May 6, 2026
07:57
Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
3.7K
[Genetic basis of primary hypertriglyceridemia].
1Department of Clinical and Molecular Epidemiology, 22nd Medical and Research Center, The University of Tokyo Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 12, 2013
Summary
Severe hypertriglyceridemia stems from genetic defects impacting lipoprotein lipase (LPL) activity. Mild hypertriglyceridemia arises from genetic variants and environmental factors, with potential for shared genetic bases and new therapeutic targets.
Area of Science:
- Genetics and Molecular Biology
- Metabolic Disorders
- Cardiovascular Research
Context:
- Hypertriglyceridemia, a lipid disorder, presents in severe (monogenic) and mild (polygenic) forms.
- Severe forms are linked to reduced lipoprotein lipase (LPL) activity due to mutations in genes like LPL, APOC2, GPIHBP1, LMF1, and APOA5.
- Mild hypertriglyceridemia is associated with accumulated common and rare genetic risk variants, influenced by environmental factors.
Purpose:
- To explore the genetic underpinnings of both severe and mild hypertriglyceridemia.
- To identify shared genetic bases among primary hyperlipoproteinemias.
- To highlight the role of genetic analysis in discovering therapeutic targets and improving genetic risk scoring.
Summary:
- Rare, severe hypertriglyceridemia is caused by genetic mutations severely reducing lipoprotein lipase (LPL) activity.
- Common, mild hypertriglyceridemia results from a combination of genetic variants and environmental influences.
- Genetic analysis offers insights into shared genetic bases for hyperlipoproteinemias, potential therapeutic targets, and refined risk assessment.
Impact:
- Advances understanding of the genetic architecture of hypertriglyceridemia.
- Suggests novel therapeutic strategies targeting genetic pathways.
- Provides a foundation for developing more accurate genetic risk scores for hypertriglyceridemia.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:26Type II Diabetes I: Introduction
57
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
57
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
859
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
859
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:24Overview of Lipid Metabolism
7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84